Zug, Switzerland & Egham, UK – 21 June 2023 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces the appointment of Lee Morley as Non-Executive Director to the Board.

Lee brings more than 30 years of experience as a leader and executive in the biopharmaceutical industry, with extensive knowledge of commercialisation, pricing, reimbursement and product launch strategy. Most recently, he was Chief Executive Officer at EUSA Pharma, leading the company through a period of significant and sustained growth, culminating in a €750M acquisition by Recordati (BIT: REC) in 2022. During his time at EUSA Pharma, he led the company’s transition from specialty pharma to oncology and rare disease, driving the company’s sales from €20M to €150M.

Prior to this, Lee served as Head of Commercial at Jazz Pharmaceuticals (NASDAQ: JAZZ), overseeing commercial programmes across European and International Markets and restructuring the business to facilitate new product launches across Europe. Previously, he was Director, Sales Effectiveness at Zeneus Pharma and held several roles at Merck Sharp and Dohme (NYSE: MRK). He holds a degree in Chemistry and Management Studies from Kings College London.

Emma Johnson, Chief Executive Officer of Essential Pharma, commented: “We are excited to welcome Lee to the Essential Pharma Board as we seek to deliver on our ambitious growth strategy, ensuring that patients have sustainable access to the mature essential medicines they depend on. Having worked alongside him during our time at EUSA Pharma, I know that Essential Pharma will benefit enormously from his insights and experience as a leading executive in specialty pharma.”

Commenting on his appointment, Lee Morley said: “Essential Pharma plays a key role in ensuring the long-term, structured supply of established medicines to patients globally. I look forward to working with the Board and supporting Essential Pharma’s ambitious growth plans.”